GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (FRA:0TB) » Definitions » PB Ratio

Theravance Biopharma (FRA:0TB) PB Ratio : 2.23 (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-16), Theravance Biopharma's share price is €8.65. Theravance Biopharma's Book Value per Share for the quarter that ended in Dec. 2023 was €3.88. Hence, Theravance Biopharma's PB Ratio of today is 2.23.

The historical rank and industry rank for Theravance Biopharma's PB Ratio or its related term are showing as below:

FRA:0TB' s PB Ratio Range Over the Past 10 Years
Min: 1.32   Med: 2.44   Max: 52.36
Current: 2.23

During the past 12 years, Theravance Biopharma's highest PB Ratio was 52.36. The lowest was 1.32. And the median was 2.44.

FRA:0TB's PB Ratio is ranked better than
53.93% of 1322 companies
in the Biotechnology industry
Industry Median: 2.54 vs FRA:0TB: 2.23

During the past 12 months, Theravance Biopharma's average Book Value Per Share Growth Rate was -34.60% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Theravance Biopharma was -38.20% per year. The lowest was -69.90% per year. And the median was -54.05% per year.

Back to Basics: PB Ratio


Theravance Biopharma PB Ratio Historical Data

The historical data trend for Theravance Biopharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma PB Ratio Chart

Theravance Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.63 2.51

Theravance Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 1.94 1.73 2.51 2.14

Competitive Comparison of Theravance Biopharma's PB Ratio

For the Biotechnology subindustry, Theravance Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theravance Biopharma's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's PB Ratio falls into.



Theravance Biopharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Theravance Biopharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=8.65/3.881
=2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Theravance Biopharma  (FRA:0TB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Theravance Biopharma PB Ratio Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Theravance Biopharma (FRA:0TB) Business Description

Traded in Other Exchanges
Address
Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma (FRA:0TB) Headlines

No Headlines